No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
557745 |
1. Apply sex-specific ruleNone |
557745 |
2. Check conditionsNone |
557745 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
403 |
4. Check minimum number of eventsNone |
403 |
5. Include endpointsNone |
403 |
6. Filter based on genotype QC (FinnGen only) |
365 |
Control definitions (FinnGen only)
- Control exclude
- G6_DEMYEL
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- G35-G37
- Name in latin
- Alia demyelinatio disseminata acuta
Similar endpoints
↥List of similar endpoints to
Other acute disseminated demyelination
based on the number of shared cases.
Similar with more cases:
- Demyelinating diseases of the central nervous system
- Autoimmune diseases
- Used for control exclusion in common control thyroid runs
- Neurological diseases
- Neurological diseases, wide definition
Similar with less cases:
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 2214 | 1475 | 720 |
| Only index persons | 2052 | 1408 | 644 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.03 | 0.04 | 0.02 |
| Only index persons | 0.04 | 0.05 | 0.02 |
| Median age at first event (years) | |||
| Whole population | 38.77 | 38.00 | 40.00 |
| Only index persons | 37.80 | 37.69 | 38.05 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 365 | 273 | 92 |
| Unadjusted period prevalence (%) | 0.08 | 0.10 | 0.04 |
| Median age at first event (years) | 38.15 | 37.11 | 41.22 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 388
- Matched controls
- 3880
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
G36.9
ICD-10 Finland
Acute disseminated demyelination, unspecified
+∞
322.8
263
*
G35
ICD-10 Finland
Multiple sclerosis
3948.9
316.8
262
*
109
Kela drug reimbursment
Multiple sclerosis
+∞
240.5
205
*
303
Kela drug reimbursment
Dimethyl fumarate, interferon beta, glatiramer acetate and teriflunomid (Multiple sclerosis)
+∞
227.1
195
*
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
22.5
214.6
206
186
157
Kela drug reimbursment
Dimethyl fumarate, glatiramer acetate, interferon beta and teriflunomid (Multiple sclerosis)
+∞
211.4
183
*
TAB00
NOMESCO Finland
Lumbar puncture
20.1
150.0
132
97
L03AB07
ATC
interferon beta-1a; parenteral
+∞
128.5
116
*
H46
ICD-10 Finland
Optic neuritis
200.8
114.3
114
8
N04BB01
ATC
amantadine; oral
73.6
113.6
62
10
G37.9
ICD-10 Finland
Demyelinating disease of central nervous system, unspecified
+∞
110.9
101
*
G36.0
ICD-10 Finland
Neuromyelitis optica [Devic]
+∞
106.2
97
*
L03AX13
ATC
glatiramer acetate; parenteral
+∞
102.8
94
*
AA1BG
NOMESCO Finland
Standard MRI examination of brain with high intensity magnet
9.3
90.8
138
217
AA1CM
NOMESCO Finland
Extensive MRI examination of brain with 3 Tesla magnet
27.7
83.9
59
25
N86
ICPC
Multiple sclerosis
969.9
82.7
78
*
XCK00
NOMESCO Finland
Perimetry
12.8
73.4
78
75
AA1DG
NOMESCO Finland
Very extensive MRI examination of brain with high intensity magnet
16.5
71.5
64
46
NA7CG
NOMESCO Finland
Spine and spinal cord extensive MRI examination with high intensity magnet
33.8
69.1
45
15
164
Kela drug reimbursment
Fingolimod
+∞
67.7
63
*
XA800
NOMESCO Finland
Neuropsychological investigation
11.0
67.0
79
88
NA1CG
NOMESCO Finland
Cervical spine extensive MRI examination with high intensity magnet
21.1
64.1
50
27
ZX120
NOMESCO Finland
Intravenous
7.5
57.9
98
168
353
Kela drug reimbursment
Cladribine and fingolimod
+∞
57.8
54
*
M03BX01
ATC
baclofen; systemic
17.9
54.7
46
29
L04AA31
ATC
[U] teriflunomide
+∞
54.5
51
*
L04AA27
ATC
[U] fingolimod
+∞
52.3
49
*
L04AX07
ATC
dimethyl fumarate; oral
+∞
51.2
48
*
N07XX09
ATC
[U] dimethyl fumarate
+∞
51.2
48
*
NA1BG
NOMESCO Finland
Cervical spine MRI examination with high intensity magnet
8.0
48.5
73
109
L03AB08
ATC
interferon beta-1b; parenteral
+∞
47.9
45
*
Z01.0
ICD-10 Finland
Examination of eyes and vision
4.6
41.9
135
405
R29.8
ICD-10 Finland
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
5.8
39.8
85
180
R20.2
ICD-10 Finland
Paraesthesia of skin
5.6
39.4
87
190
XKD06
NOMESCO Finland
Physiologic investigation of micturition
13.1
37.3
37
31
XCD10
NOMESCO Finland
Electrophysiological examination of eye
14.1
37.0
35
27
Z03.3
ICD-10 Finland
Observation for suspected nervous system disorder
7.6
36.7
56
84
2AB04, ,
NOMESCO Finland
203.9
36.4
37
*
NA2BG
NOMESCO Finland
Thoracal spine MRI examination with high intensity magnet
11.0
36.0
40
40
H53.2
ICD-10 Finland
Diplopia
10.3
35.1
41
44
XKC03
NOMESCO Finland
Water cystometry
11.0
35.0
39
39
G97.0
ICD-10 Finland
Cerebrospinal fluid leak from spinal puncture
14.4
34.4
32
24
G04BD12
ATC
mirabegron; oral
5.5
32.0
69
146
UKC02
NOMESCO Finland
Cystoscopy
4.6
29.2
80
207
G36.8
ICD-10 Finland
Other specified acute disseminated demyelination
+∞
27.4
26
*
G04BD08
ATC
solifenacin; oral
7.4
27.3
42
63
NA2CG
NOMESCO Finland
Thoracal spine extensive MRI examination with high intensity magnet
39.9
26.6
33
9
L04AK02
ATC
teriflunomide; oral
+∞
26.3
25
*
H02AB04
ATC
methylprednisolone; systemic
3.8
26.1
97
312
N03AX12
ATC
[U] gabapentin; oral
3.6
25.8
105
359
L03AB13
ATC
peginterferon beta-1a; parenteral
+∞
22.1
21
*
F02.89*G35
ICD-10 Finland
Dementia in multiple sclerosis
+∞
22.1
21
*
N03AE01
ATC
clonazepam; systemic
5.5
21.5
44
88
L04AE01
ATC
fingolimod; oral
+∞
21.0
20
*
XKD00
NOMESCO Finland
Uroflowmetry
4.3
20.5
58
152
XCW99
NOMESCO Finland
Other investigative procedure of eye
4.3
19.8
57
151
N06BA07
ATC
modafinil; oral
48.7
19.4
23
5
R1250
NOMESCO Finland
Evaluation of functional capability
6.9
18.2
29
45
Z50.8
ICD-10 Finland
Care involving use of other rehabilitation procedures
4.5
18.2
48
119
4AA23, ,
NOMESCO Finland
+∞
17.8
17
*
G04.9
ICD-10 Finland
Encephalitis, myelitis and encephalomyelitis, unspecified
+∞
17.8
17
*
NA7DG
NOMESCO Finland
Spine and spinal cord very extensive MRI examination with high intensity magnet
16.7
17.8
28
18
G04BD09
ATC
trospium; oral
18.0
17.7
27
16
L04AX01
ATC
azathioprine; systemic
5.0
16.5
37
80
CS444
NOMESCO Finland
Visual field testing with Octopus automated perimetry
6.4
15.8
27
45
NA7BG
NOMESCO Finland
Spine and spinal cord MRI examination with high intensity magnet
47.0
15.2
18
*
TAB22
NOMESCO Finland
Stoppin epidural fluid escape with coagulated blood
14.0
14.9
25
19
O99.3
ICD-10 Finland
Mental disorders and diseases of the nervous system complicating pregnancy, childbirth and the puerperium
6.0
14.8
27
48
KC1EE
NOMESCO Finland
Ultrasound measurement of residual urine
3.9
14.7
47
134
L04AG12
ATC
ofatumumab; parenteral
+∞
14.7
14
*
CK2X4
NOMESCO Finland
Optical coherence tomography (OCT) of ocular fundus
3.8
14.7
49
144
TKC22
NOMESCO Finland
Catheterisation instruction
20.1
14.4
21
11
Z2445
NOMESCO Finland
Psychologist
4.4
14.4
38
94
N99
ICPC
Neurological disease other
21.0
13.9
20
10
N31.9
ICD-10 Finland
Neuromuscular dysfunction of bladder, unspecified
24.9
13.9
19
8
G37.3
ICD-10 Finland
Acute transverse myelitis in demyelinating disease of central nervous system
+∞
13.6
13
*
Z01.8
ICD-10 Finland
Other specified special examinations
2.5
13.5
114
562
KH1AE
NOMESCO Finland
Urinary tract ultrasound examination
4.5
13.0
33
79
L04AA40
ATC
cladribine; oral
+∞
12.6
12
*
G36.1
ICD-10 Finland
Acute and subacute haemorrhagic leukoencephalitis [Hurst]
+∞
12.6
12
*
GD1AA
NOMESCO Finland
Thorax X-ray examination
2.2
12.4
181
1116
N05CF01
ATC
zopiclone; oral
2.2
12.3
139
772
N39.4
ICD-10 Finland
Other specified urinary incontinence
3.6
12.2
43
131
XKD03
NOMESCO Finland
Urethral pressure profilometry
10.6
12.2
23
23
N39.0
ICD-10 Finland
Urinary tract infection, site not specified
2.7
11.8
74
315
WW400
NOMESCO Finland
Plasmaferesis
+∞
11.5
11
*
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
2.8
11.4
62
244
N28
ICPC
Limited function/disability (N)
15.7
11.4
18
12
N03AX16
ATC
[U] pregabalin
2.3
11.3
105
536
N06AX21
ATC
duloxetine; oral
2.6
11.0
75
331
G95.8
ICD-10 Finland
Other specified diseases of spinal cord
44.7
11.0
13
*
J01EA01
ATC
trimethoprim; systemic
2.2
10.8
122
672
KCV12
NOMESCO Finland
Urinary bladder endoscopic botulin therapy
22.2
10.8
15
7
AA1AD
NOMESCO Finland
CT of head and brain
2.3
10.6
105
548
L28
ICPC
Limited function/disability (L)
2.6
10.5
71
312
XCK10
NOMESCO Finland
Photography of fundus of eye
3.2
10.5
43
144
H48.1*G35
ICD-10 Finland
Retrobulbar neuritis in multiple sclerosis
+∞
10.5
10
*
R35
ICD-10 Finland
Polyuria
3.6
10.4
35
103
A02BC02
ATC
pantoprazole; systemic
2.1
10.3
274
2058
R4150
NOMESCO Finland
Neuropsychological rehabilitation
10.5
10.1
19
19
Z3226
NOMESCO Finland
Physiotherapist
2.4
10.1
83
400
G04BD11
ATC
fesoterodine; oral
9.1
9.9
20
23
A28
ICPC
Limited function/disability NOS
2.7
9.9
56
225
R90.8
ICD-10 Finland
Other abnormal findings on diagnostic imaging of central nervous system
9.5
9.6
19
21
R42
ICD-10 Finland
Dizziness and giddiness
2.3
9.6
91
465
G04BD07
ATC
tolterodine; oral
4.4
9.5
24
57
H51.2
ICD-10 Finland
Internuclear ophthalmoplegia
+∞
9.4
9
*
SPAT1229
SPAT
Assessment of need for aid
4.1
9.3
26
67
SPAT1216
SPAT
Assessment of functional ability
2.7
9.0
53
217
R4120
NOMESCO Finland
Occupational therapy
3.1
8.9
39
136
R2130
NOMESCO Finland
Counselling and guidance which enhance independent living
3.0
8.7
40
143
N02BF01
ATC
gabapentin; oral
2.5
8.5
57
249
N32.83
ICD-10 Finland
Nozzle synergy in the bladder neck
92.0
8.4
9
*
Z50.9
ICD-10 Finland
Care involving use of rehabilitation procedure, unspecified
3.7
8.4
27
77
H53.1
ICD-10 Finland
Subjective visual disturbances
2.9
8.3
41
153
CS494
NOMESCO Finland
Other visual field testing
7.8
8.3
18
24
A02BA02
ATC
ranitidine; systemic
2.3
8.0
68
330
R5110, ,
SPAT
3.0
8.0
37
133
CK2S4
NOMESCO Finland
Plain photography of ocular fundus
3.4
7.7
28
87
N29
ICPC
Neurological sympt/complt other
8.3
7.7
16
20
U13
ICPC
Bladder symptom/complaint other
6.4
7.6
19
31
H53.4
ICD-10 Finland
Visual field defects
6.7
7.5
18
28
SPAT1230
SPAT
Aid fitting and borrowing and monitoring of use
2.3
7.4
59
279
NA3BG
NOMESCO Finland
Lumbar spine MRI examination with high intensity magnet
2.4
7.3
52
233
L04AA52
ATC
[U] ofatumumab; parenteral
+∞
7.3
7
*
CA1CG
NOMESCO Finland
Eye and orbita extensive MRI examination with high intensity magnet
16.1
7.3
11
7
G04BD04
ATC
oxybutynin; oral, transdermal
3.5
7.1
24
71
WD325
NOMESCO Finland
Demanding therapy of methastized malignancy with biomodifiers
10.3
7.1
13
13
H57.1
ICD-10 Finland
Ocular pain
3.1
7.0
30
103
SPAT1220
SPAT
Assessment of need for rehabilitation and/or rehabilitation plan
3.5
6.9
24
72
SPAT1215
SPAT
Assessment of need for medical rehabilitation
3.8
6.6
20
55
G51.0
ICD-10 Finland
Bell palsy
4.2
6.4
17
42
SPAT1262
SPAT
Handing over of treatment supplies
2.2
6.4
58
289
R33
ICD-10 Finland
Retention of urine
3.2
6.3
25
82
6BA02, ,
NOMESCO Finland
18.4
6.3
9
5
N31.1
ICD-10 Finland
Reflex neuropathic bladder, not elsewhere classified
18.4
6.3
9
5
N02AE01
ATC
buprenorphine; parenteral, sublingual, transdermal
2.4
6.3
44
196
L01BB04
ATC
cladribine; systemic
+∞
6.3
6
*
H47.0
ICD-10 Finland
Disorders of optic nerve, not elsewhere classified
27.2
6.2
8
*
H47.2
ICD-10 Finland
Optic atrophy
27.2
6.2
8
*
A03FA02
ATC
cisapride; oral, rectal
3.0
6.2
28
99
SPAT1226
SPAT
Implementation of occupational therapy rehabilitation plan
6.5
6.2
15
24
Z3231
NOMESCO Finland
Registered nurse
1.8
6.1
109
688
TKC20
NOMESCO Finland
Catheterisation of bladder
3.1
6.1
25
84
H02AB07
ATC
prednisone; oral
2.2
6.0
54
267
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
96
55
22.86
122.09
1.3
1.1
—
—
—
0
0
65
27
28.72
93.39
1.2
1.1
43.81
28.13
mg/l
2.66
59
22
62
23
31.89
92.61
1.2
1.0
—
—
—
0
0
144
277
7.68
78.04
5.2
2.7
9.99
10.14
g/l
0.18
138
259
50
23
24.81
68.63
1.2
1.2
0.83
0.50
ratio
4.88
35
15
44
22
22.43
58.17
5.0
1.9
423.62
582.29
e6/l
0.91
39
14
53
40
15.19
57.34
1.2
1.1
—
—
—
0
0
51
43
13.50
51.59
1.2
1.1
—
—
—
0
0
42
25
18.72
51.23
1.1
1.1
0.99
1.09
u/l
0.36
12
15
48
39
13.90
49.60
1.1
1.1
—
—
—
0
0
67
90
8.79
48.66
1.3
1.2
153.03
14.67
e6/l
0.47
59
67
67
92
8.59
47.76
1.3
1.3
604.15
169.81
e6/l
0.44
59
72
75
120
7.51
46.77
1.8
1.5
44.10
0.01
iu/ml
—
8
18
36
19
20.78
46.28
1.2
1.1
1768.44
1842.58
miu/ml
0.09
36
19
65
91
8.38
45.52
1.2
1.2
3.53
3.58
mmol/l
0.14
59
86
35
20
19.14
43.36
5.6
2.8
—
—
—
0
0
307
1981
3.63
25.14
19.0
9.9
3.75
4.01
e9/l
1.52
291
1743
261
1544
3.11
24.56
3.2
2.5
89.96
74.79
nmol/l
10.44
249
1453
84
267
3.74
22.81
1.5
1.2
—
29.80
—
0
22
88
297
3.54
21.77
2.7
2.2
18.83
17.04
au/ml
—
6
33
144
658
2.89
21.19
4.6
2.4
4.94
8.40
e6/l
1.55
128
590
29
38
8.17
21.09
1.1
1.1
—
—
—
0
0
213
1303
2.41
16.02
7.6
4.5
37.34
36.87
g/l
0.66
208
1250
173
979
2.38
15.36
6.2
2.7
22.79
119.69
e6/l
0.77
145
728
26
27
10.24
13.43
1.1
1.3
2.15
1.89
mmol/l
0.25
26
27
149
837
2.27
12.98
6.1
2.6
0.15
0.37
e6/l
1.73
122
588
243
1711
2.12
11.38
8.5
6.1
10.59
10.43
umol/l
0.09
234
1642
251
1800
2.12
11.06
7.0
3.3
0.00
0.00
estimate
0.50
52
376
23
28
8.66
10.97
7.2
2.7
47.07
45.26
%
0.13
15
12
250
1823
2.04
10.11
6.9
3.3
0.00
11.98
estimate
1.08
51
379
251
1835
2.04
10.05
7.0
3.4
0.00
0.00
estimate
-0.00
50
352
94
498
2.17
9.01
5.1
2.4
0.46
0.94
e6/l
1.73
58
241
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
16
17
9.76
8.35
1.3
1.2
—
—
—
0
0
310
2539
2.10
7.94
11.4
7.7
76.21
74.95
u/l
0.19
301
2427
85
456
2.11
7.80
5.5
2.5
5.92
3.64
e6/l
0.37
48
202
12
8
15.42
7.76
1.0
1.1
—
—
—
0
0
12
8
15.42
7.76
1.0
1.3
—
—
—
0
0
237
1827
1.76
6.72
5.9
4.4
6.48
6.42
mmol/l
0.16
226
1698
37
149
2.64
6.49
1.5
1.3
—
—
—
0
0
144
980
1.75
6.23
8.3
3.4
0.00
0.01
estimate
0.99
51
359
10
8
12.79
6.11
1.0
1.5
—
—
—
0
0
10
9
11.36
5.82
1.0
1.3
—
—
—
0
0
13
19
7.04
5.78
1.3
1.1
—
—
—
0
0
10
10
10.23
5.56
1.0
1.6
—
—
—
0
0
64
349
2.00
5.53
7.0
5.8
1.04
1.02
mmol/l
0.23
59
325
12
17
7.25
5.48
1.2
1.2
—
—
—
0
0
194
1468
1.64
5.44
8.7
6.4
1.21
1.21
mmol/l
0.03
169
1290
76
448
1.87
5.21
2.0
1.9
—
—
—
0
0
40
187
2.27
5.12
2.1
2.1
2.48
7.03
iu/ml
—
9
45
9
9
10.20
5.05
1.0
1.2
—
—
—
0
0
303
2601
1.75
4.96
6.6
3.2
47.31
39.16
u/l
0.99
296
2513
67
391
1.86
4.72
1.6
1.6
1187.03
1215.25
nmol/l
0.09
56
305
164
1240
1.56
4.32
6.8
3.1
29.54
29.61
u/l
0.01
156
1181
58
334
1.87
4.26
3.7
3.9
32.43
32.03
%
0.10
47
238
170
1304
1.54
4.15
7.6
5.7
1.21
1.22
mmol/l
0.31
161
1224
116
817
1.60
4.11
1.8
1.6
20.64
20.79
nmol/l
0.04
107
726
76
485
1.71
3.95
2.8
2.3
15.49
14.24
umol/l
0.62
71
452
44
238
1.96
3.89
4.0
2.4
0.07
0.15
e6/l
1.50
44
226
6
5
12.16
3.77
1.0
1.0
—
—
—
0
0
6
5
12.16
3.77
1.0
1.0
—
—
—
0
0
47
263
1.90
3.77
2.8
2.2
371.82
6133.20
u/l
2.05
11
116
313
3389
0.60
3.53
4.5
4.4
1.49
1.49
mmol/l
0.01
296
3230
53
316
1.78
3.48
2.0
1.7
—
—
—
0
0
89
610
1.60
3.48
1.8
1.6
111111546.95
22652366.50
pmol/l
0.36
81
543
8
14
5.81
3.35
1.0
1.0
—
—
—
0
0
80
543
1.60
3.25
3.4
3.2
143.60
224.88
ng/l
0.23
41
334
112
826
1.50
3.13
2.6
2.1
3.03
2.71
mg/l
0.65
102
723
11
30
3.74
3.11
1.1
1.7
—
—
—
0
0
10
25
4.08
3.10
1.4
1.1
—
—
—
0
0
23
106
2.24
3.09
1.6
1.7
—
—
—
0
0
316
3398
0.62
3.09
4.6
4.5
4.76
4.79
mmol/l
0.20
300
3259
68
450
1.62
3.06
3.0
2.2
2.51
2.40
g/l
0.81
62
419
320
3429
0.62
3.03
4.9
4.9
2.83
2.86
mmol/l
0.17
304
3278
108
796
1.49
3.01
7.5
3.4
1.02
1.02
kg/l
0.21
87
519
5
5
10.11
2.98
1.0
1.0
—
—
—
0
0
8
17
4.78
2.93
1.1
1.3
—
—
—
0
0
173
1405
1.42
2.87
7.6
3.2
0.04
0.05
estimate
0.05
45
313
288
2563
1.48
2.86
5.0
4.2
9.29
9.45
mm/h
0.09
277
2438
62
409
1.61
2.82
2.9
2.3
24.37
23.94
%
0.07
55
385
35
197
1.85
2.79
1.4
1.3
137.00
242.21
miu/ml
1.80
12
102
10
29
3.51
2.71
4.3
1.6
1.29
1.36
promille
—
10
22
10
29
3.51
2.71
1.1
1.1
104.30
112.41
pmol/l
—
10
29
60
397
1.60
2.70
6.7
2.7
4.65
6.71
umol/l
1.19
51
349
13
50
2.66
2.55
1.5
1.5
—
—
—
0
0
299
3222
0.69
2.41
3.9
3.8
1.24
1.25
mmol/l
0.14
281
3047
47
302
1.63
2.39
2.2
1.8
—
—
—
0
0
130
1039
1.38
2.26
3.1
2.4
54.06
65.65
u/l
1.12
123
984
135
1087
1.37
2.23
6.5
2.7
0.00
0.03
estimate
1.34
44
301
135
1088
1.37
2.22
3.9
3.3
26.36
96.78
ng/l
0.53
83
601
24
130
1.90
2.18
1.8
1.7
—
—
—
0
0
361
3428
1.76
2.17
21.0
12.6
19.06
20.09
mg/l
0.23
291
2772
13
55
2.41
2.14
2.8
4.3
28.77
34.70
umol/l
0.37
13
50
5
10
5.05
2.07
1.0
1.0
87.60
95.80
%
—
5
10
36
545
0.63
1.95
2.1
1.9
3.36
3.37
ratio
0.02
27
413
153
1280
1.32
1.91
2.4
1.9
104.65
99.07
pmol/l
0.64
86
674
25
144
1.79
1.90
2.9
1.7
0.21
0.23
g/l
0.75
25
139
216
1899
1.31
1.87
3.5
3.2
111.00
82.58
ug/l
1.07
205
1816
5
12
4.21
1.83
1.2
5.1
0.60
1.00
index
—
5
12
16
80
2.04
1.82
1.3
2.8
3.57
1.72
index
—
7
42
373
3597
1.96
1.81
23.0
10.6
28.11
26.49
u/l
0.60
373
3531
11
47
2.38
1.79
1.5
1.1
—
—
—
0
0
64
471
1.43
1.77
2.7
2.0
—
—
—
0
0
13
61
2.17
1.73
1.1
1.3
—
—
—
0
0
28
172
1.68
1.72
5.5
3.4
5.20
5.11
kpa
0.25
28
167
43
294
1.52
1.72
3.4
4.5
221.49
232.79
u/l
0.42
43
287
25
150
1.71
1.68
3.0
1.7
1.09
1.19
g/l
0.93
25
143
20
113
1.81
1.63
1.8
1.9
—
—
—
0
0
351
3349
1.50
1.57
20.6
13.1
139.68
139.67
mmol/l
0.03
351
3291
127
1061
1.29
1.55
3.1
3.1
2.35
2.35
mmol/l
0.16
118
992
10
204
0.48
1.54
1.2
1.1
1.38
1.59
g/l
—
10
204
6
21
2.89
1.51
1.0
4.6
802.33
586.67
u/ml
—
6
21
52
381
1.42
1.49
2.6
1.9
—
—
—
0
0
9
37
2.47
1.49
1.7
1.1
—
—
—
0
0
9
38
2.40
1.46
1.7
1.1
—
—
—
0
0
9
39
2.34
1.44
1.7
1.1
—
—
—
0
0
9
39
2.34
1.44
1.7
1.1
—
—
—
0
0
370
3584
1.70
1.39
25.4
15.2
69.73
70.90
umol/l
0.29
370
3555
12
60
2.03
1.39
2.4
4.3
1.30
2.85
ratio
—
6
34
11
209
0.51
1.39
1.3
1.2
0.81
0.89
g/l
0.87
11
209
37
258
1.48
1.38
3.4
3.7
4.59
4.61
pmol/l
0.05
31
231
31
208
1.53
1.37
2.2
1.6
—
—
—
0
0
6
23
2.63
1.37
4.2
1.3
—
—
—
0
0
9
43
2.12
1.31
1.7
1.1
—
—
—
0
0
5
18
2.80
1.29
1.4
2.4
2.00
1.16
nmol/l
—
5
12
8
158
0.50
1.28
1.6
1.6
—
—
—
0
0
29
416
0.67
1.25
1.7
1.7
3.20
3.42
mmol/l
0.56
22
288
12
63
1.93
1.24
2.6
3.6
—
5410.00
—
0
5
97
805
1.27
1.23
2.5
2.6
301.74
318.79
umol/l
1.08
92
735
340
3261
1.34
1.12
17.9
11.6
93.62
89.73
ml/min/173m2
3.08
319
2984
8
40
2.02
1.12
1.4
1.4
—
—
—
0
0
37
270
1.41
1.12
6.7
7.9
0.77
0.93
mmol/l
0.09
27
220
14
81
1.76
1.10
2.4
1.5
—
—
—
0
0
21
138
1.55
1.05
1.1
1.3
—
—
—
0
0
37
274
1.39
1.04
3.9
2.5
0.22
0.23
g/l
0.50
37
261
12
200
0.59
1.01
1.2
1.4
—
—
—
0
0
7
35
2.02
1.00
2.1
2.0
—
—
—
0
0
0
29
0.00
0.98
0.0
2.7
—
—
—
0
0
11
62
1.80
0.95
1.5
1.9
—
—
—
0
0
8
42
1.92
0.89
1.3
1.2
—
—
—
0
0
10
57
1.77
0.84
1.3
1.4
—
—
—
0
0
10
57
1.77
0.84
1.3
1.4
—
—
—
0
0
8
47
1.72
0.81
1.5
1.4
—
—
—
0
0
25
337
0.72
0.80
1.4
1.5
737.98
981.77
mu/l
1.02
18
271
94
816
1.20
0.79
1.9
1.8
0.64
0.90
mg/l
1.09
70
636
0
25
0.00
0.79
0.0
1.1
—
—
—
0
0
0
25
0.00
0.79
0.0
1.6
—
—
—
0
0
14
90
1.58
0.79
3.6
2.4
26.21
24.38
mmol/l
0.74
14
90
335
3239
1.25
0.78
6.4
5.5
1.72
1.79
mu/l
0.66
322
3091
79
676
1.21
0.77
2.9
3.2
867.91
717.08
ng/l
0.12
65
554
31
236
1.34
0.77
10.4
3.3
1.65
1.74
mmol/l
0.05
26
202
43
344
1.28
0.76
7.6
6.5
104.67
104.26
mmol/l
0.25
43
344
16
109
1.49
0.72
1.9
2.2
1.51
1.37
g/l
0.30
16
99
5
26
1.93
0.71
1.0
1.1
—
—
—
0
0
14
94
1.51
0.67
1.1
1.3
—
1.23
—
0
6
39
315
1.26
0.65
4.2
2.3
39.09
32.86
u/l
0.34
33
274
49
407
1.23
0.65
3.6
4.0
20.25
23.21
%
0.47
20
158
5
29
1.73
0.64
1.6
2.2
—
—
—
0
0
8
49
1.65
0.62
1.3
1.2
—
—
—
0
0
0
21
0.00
0.60
0.0
1.7
—
0.87
—
0
5
11
74
1.50
0.54
2.5
1.3
—
—
—
0
0
9
62
1.46
0.53
1.8
1.9
—
—
—
0
0
6
40
1.51
0.52
1.0
1.1
—
—
—
0
0
14
187
0.74
0.46
1.9
2.2
5.06
2.36
mg/l
—
9
129
134
1436
0.90
0.44
1.8
1.9
1.32
1.38
mmol/l
0.42
113
1272
9
131
0.68
0.43
1.4
1.7
—
—
—
0
0
11
78
1.42
0.43
2.0
2.3
—
—
—
0
0
96
881
1.12
0.40
1.6
1.5
—
—
—
0
0
289
2807
1.12
0.40
5.1
4.7
14.55
14.36
pmol/l
0.71
270
2669
106
979
1.11
0.40
1.3
1.3
0.68
2.03
u/ml
1.80
26
295
7
104
0.67
0.40
1.3
1.6
—
—
—
0
0
8
61
1.32
0.39
3.5
2.3
4.85
7.78
pmol/l
—
8
61
14
181
0.77
0.39
2.2
2.0
—
—
—
0
0
86
786
1.12
0.39
2.7
2.0
—
—
—
0
0
18
224
0.79
0.38
1.7
1.6
316.44
307.70
mu/l
0.06
18
205
19
152
1.26
0.37
2.1
1.8
—
—
—
0
0
168
1597
1.09
0.35
3.1
2.6
—
—
estimate
—
0
0
29
246
1.19
0.35
1.6
2.1
40.93
42.77
u/ml
0.03
29
234
103
959
1.10
0.33
1.7
1.7
—
—
—
0
0
6
46
1.31
0.33
5.0
1.9
15.73
16.91
%
—
6
46
17
137
1.25
0.32
6.2
2.2
0.50
0.62
%
1.08
17
137
20
240
0.82
0.31
1.0
1.0
—
—
—
0
0
22
184
1.21
0.31
1.2
1.5
0.39
0.29
mg/l
—
6
74
7
54
1.30
0.30
1.0
1.6
—
—
—
0
0
31
269
1.17
0.30
3.2
3.0
—
—
—
0
0
10
77
1.31
0.26
1.0
1.5
—
—
—
0
0
9
74
1.22
0.25
1.1
1.1
—
—
—
0
0
91
856
1.08
0.24
5.9
3.9
8.64
10.08
mg/mmol
0.13
54
523
79
739
1.09
0.24
2.1
2.2
—
—
—
0
0
5
38
1.32
0.23
1.4
1.2
—
—
—
0
0
5
39
1.29
0.23
1.8
1.2
—
65.00
—
0
6
10
79
1.27
0.22
1.4
1.4
156.00
159.59
au/ml
—
5
23
305
3099
0.93
0.22
5.5
5.2
37.52
37.97
mmol/mol
0.39
296
2976
0
11
0.00
0.21
0.0
1.4
—
—
—
0
0
0
10
0.00
0.21
0.0
1.3
—
—
—
0
0
0
10
0.00
0.21
0.0
1.1
—
—
—
0
0
0
12
0.00
0.21
0.0
1.2
—
—
—
0
0
5
43
1.16
0.21
1.2
1.4
—
—
—
0
0
5
43
1.16
0.21
1.2
1.4
—
—
—
0
0
0
13
0.00
0.21
0.0
1.0
—
—
—
0
0
0
14
0.00
0.20
0.0
1.3
—
—
—
0
0
21
239
0.87
0.20
1.1
1.5
—
—
—
0
0
16
137
1.18
0.19
13.9
2.9
24.06
24.34
mmol/l
0.19
16
137
23
204
1.14
0.18
1.4
1.6
—
—
—
0
0
33
302
1.10
0.16
9.1
5.7
—
—
—
0
0
10
83
1.21
0.15
1.0
1.5
—
—
—
0
0
35
323
1.09
0.15
2.7
2.8
0.75
0.74
ug/l
0.04
22
178
12
102
1.18
0.15
1.7
1.6
—
—
—
0
0
25
227
1.11
0.14
1.7
1.4
—
—
—
0
0
87
835
1.05
0.14
1.3
1.3
13.07
28.55
iu/ml
3.12
21
254
14
122
1.15
0.14
1.0
1.1
—
5.52
—
0
21
9
106
0.85
0.13
1.6
1.2
—
—
—
0
0
9
107
0.84
0.13
1.6
1.1
—
—
—
0
0
13
148
0.87
0.12
1.8
1.7
0.64
6.45
u/ml
—
5
45
19
172
1.11
0.11
6.0
6.2
24.02
24.64
mmol/l
0.50
19
172
22
202
1.09
0.10
1.6
1.5
—
—
—
0
0
17
154
1.11
0.10
1.6
1.4
—
—
—
0
0
5
44
1.14
0.10
1.2
1.4
—
—
—
0
0
5
44
1.14
0.10
1.2
1.4
—
—
—
0
0
5
44
1.14
0.10
1.2
1.4
—
—
—
0
0
5
44
1.14
0.10
1.2
1.4
—
—
—
0
0
5
63
0.79
0.08
1.2
1.9
12.80
13.19
%
—
5
63
36
342
1.06
0.08
1.6
1.3
218.09
168.29
u/ml
0.22
18
147
79
767
1.04
0.08
1.4
1.3
4.96
10.27
u/ml
0.82
28
312
7
66
1.06
0.08
1.0
1.5
—
—
—
0
0
6
73
0.82
0.07
4.5
2.7
5.48
6.44
umol/l
—
6
56
9
105
0.85
0.06
1.4
1.5
51.66
49.54
ug/l
—
9
105
318
3198
0.97
0.06
4.5
4.2
5.76
5.73
mmol/l
0.14
301
3015
11
100
1.10
0.05
1.3
1.5
—
—
—
0
0
10
91
1.10
0.04
1.0
1.2
—
—
—
0
0
70
688
1.02
0.03
2.0
2.0
—
—
—
0
0
268
2690
0.99
0.02
3.5
3.8
—
—
—
0
0
13
123
1.06
0.01
1.4
1.4
64.52
98.03
pmol/l
0.48
13
118
376
3753
1.06
0.01
37.0
19.6
264.91
260.85
e9/l
0.69
376
3715
376
3754
1.05
0.00
36.8
19.5
90.50
90.50
fl
0.01
376
3733
25
249
1.00
0.00
2.8
2.4
73.00
77.32
ml/min/173m2
—
7
111
376
3755
1.04
0.00
37.0
19.8
40.69
40.67
%
0.03
376
3731
376
3755
1.04
0.00
36.9
19.6
4.52
4.53
e12/l
0.07
376
3708
376
3756
1.03
0.00
37.0
19.7
135.53
135.96
g/l
0.26
376
3735
24
244
0.98
0.00
1.5
1.4
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
0.01
—
0
5
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
4.4
—
99.62
—
0
8
9
99
0.91
-0.00
1.2
1.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.6
—
6.10
—
0
5
0
6
0.00
-0.00
0.0
1.7
—
1.19
—
0
6
8
79
1.01
-0.00
1.8
1.3
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.3
—
—
—
0
0
7
69
1.01
-0.00
1.6
1.2
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.2
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint G6_DISSOTH and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| G6_DISSOTH | 2.024 [1.58, 2.6] | < 0.001 |
| Birth year | 0.996 [0.99, 1.0] | 0.361 |
During the follow-up period (1.1.1998 — 31.12.2019), 114 out of 1346 females with G6_DISSOTH died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| G6_DISSOTH | 2.036 [1.57, 2.63] | < 0.001 |
| Birth year | 0.988 [0.98, 1.0] | 0.018 |
During the follow-up period (1.1.1998 — 31.12.2019), 94 out of 622 males with G6_DISSOTH died.
Mortality risk
Mortality risk for people of age
years, who have G6_DISSOTH.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.179% | 0.402% |
| 5 | 1.097% | 2.427% |
| 10 | 3.192% | 6.325% |
| 15 | 6.203% | 11.838% |
| 20 | 10.507% | 19.86% |
Relationships between endpoints
↥Index endpoint: G6_DISSOTH – Other acute disseminated demyelination
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data